1. Search Result
Search Result
Results for "

nerve terminals

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

1

Fluorescent Dye

8

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1348

    Drug Metabolite Neurological Disease
    Dimethadione is the primary metabolite of trimethadione. Dimethadione causes depression of neuromuscular transmission. Dimethadione primarily decreases transmitter release from the nerve terminal .
    Dimethadione
  • HY-A0296
    Chlormethiazole hydrochloride
    2 Publications Verification

    Clomethiazole hydrochloride

    Others Neurological Disease
    Clomethiazole hydrochloride is a anticonvulsant. Clomethiazole hydrochloride is neuroprotective and prevents the degeneration of serotonergic nerve terminals induced by 3,4-methylenedioxymethamphetamine (MDMA) .
    Chlormethiazole hydrochloride
  • HY-B0800
    Guanethidine sulfate
    1 Publications Verification

    Guanethidine monosulfate

    Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Guanethidine sulfate (Guanethidine monosulfate), an antihypertensive agent, is an adrenergic neurone blocking agent. Guanethidine sulfate enters noradrenergic nerve terminals by the neuronal amine carrier .
    Guanethidine sulfate
  • HY-41076

    Calcium Channel CDK Neurological Disease
    Ca 2+ channel agonist 1 is an agonist of N-type Ca 2+ channel and an inhibitor of Cdk2, with EC50s of 14.23 μM and 3.34 μM, respectively, and is used as a potential treatment for motor nerve terminal dysfunction.
    Ca2+ channel agonist 1
  • HY-P10282

    CaMK Neurological Disease
    Synapsin I-(3-13), a substrate for CaMK1, is a glycoprotein. Synapsin I is a phosphoprotein that coats the cytoplasmic side of synaptic vesicles and regulates their trafficking within nerve terminals .
    Synapsin I-(3-13)
  • HY-D1517

    Fluorescent Dye Others
    FM 2-10 is a fluorescent dye. FM 2-10 is a less hydrophobic version of FM 1-43 (HY-D1434). FM 2-10 can be used for identifying actively firing neurons and investigating the mechanisms of activity-dependent vesicle cycling .
    FM 2-10
  • HY-108247

    Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Guanethidine sesquisulfate, an antihypertensive agent, is an adrenergic neurone blocking agent. Guanethidine sesquisulfate enters noradrenergic nerve terminals by the neuronal amine carrier .
    Guanethidine sesquisulfate
  • HY-105793

    mAChR Neurological Disease
    Mazaticol is an anticholinergic agent. Mazaticol blocks the muscarinic acetylcholine receptors and cholinergic nerve activity. Mazaticol is a potent 3H-QNB and 3H-PZ binding inhibitor, can bind to the M2 receptors with high affinity. Mazaticol exhibits inhibitory effects on dopamine uptake in the striatal nerve terminal. Mazaticol can be used for parkinsonian syndrome research .
    Mazaticol
  • HY-P5041

    α-synuclein Neurological Disease
    α-Synuclein (34-45) (human) is the 34-45 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a Parkinson's disease (PD) biomarker .
    α-Synuclein (34-45) (human)
  • HY-P5044

    α-synuclein Neurological Disease
    α-Synuclein (45-54) (human) is the 45-54 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .
    α-Synuclein (45-54) (human)
  • HY-P5046

    α-synuclein Neurological Disease
    α-Synuclein (71-82) (human) is the 71-82 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .
    α-Synuclein (71-82) (human)
  • HY-P3140

    α-synuclein Neurological Disease
    α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .
    α-Synuclein (61-75)
  • HY-P3140A

    α-synuclein Neurological Disease
    α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .
    α-Synuclein (61-75) (TFA)
  • HY-B0800R

    Adrenergic Receptor Neurological Disease
    Guanethidine (sulfate) (Standard) is the analytical standard of Guanethidine (sulfate). This product is intended for research and analytical applications. Guanethidine sulfate (Guanethidine monosulfate), an antihypertensive agent, is an adrenergic neurone blocking agent. Guanethidine sulfate enters noradrenergic nerve terminals by the neuronal amine carrier .
    Guanethidine sulfate (Standard)
  • HY-14608S12

    L-Glutamic acid-14C

    iGluR Ferroptosis Apoptosis Neurological Disease
    L-Glutamic acid-14C is L-Glutamic acid (HY-14608) labeled with the radioactive isotope carbon-14. L-Glutamic acid is an excitatory amino acid neurotransmitter and an agonist for all subtypes of glutamate receptors (metabotropic, NMDA, and AMPA). L-Glutamic acid acts as an agonist in the release of DA from dopaminergic nerve terminals and can be used in the study of neurological diseases .
    L-Glutamic acid-14C
  • HY-110220

    TRP Channel Neurological Disease
    CIM0216, a synthetic TRPM3 ligand, acts as a potent and selective agonist of TRPM3. CIM0216 exhibits selectivity for TRPM3 over TRPM1, TRPM2 and TRPM4-8. CIM0216 acts in a TRPM3-dependent manner to induce pain and evoke neuropeptide release from sensory nerve terminals in vitro. CIM0216 is a powerful tool for studies of the physiological functions of TRPM3, and can be used for neurogenic inflammation research .
    CIM0216
  • HY-P6437

    Dynamin Cardiovascular Disease Neurological Disease
    Drp1 peptide inhibitor P110 (Compound P110) is a selective Drp1 peptide inhibitor with neuroprotective properties. Drp1 peptide inhibitor P110 can inhibit the activation of Drp1, prevent MPTP-induced Drp1 mitochondrial translocation, and alleviate MPTP-induced dopaminergic neuron loss, dopaminergic nerve terminal damage, and behavioral deficits, and can be used in the study of Alzheimer's disease. Additionally, Drp1 peptide inhibitor P110 can reduce mitochondrial damage and organ injury in animal models of Huntington's disease, cerebral ischemic injury, and myocardial infarction .
    Drp1 peptide inhibitor P110

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: